KPV Research Overview

KPV is a tripeptide composed of lysine, proline, and valine. Its research interest derives from its correspondence to the C-terminal sequence region of alpha-melanocyte-stimulating hormone (α-MSH), a melanocortin peptide with a substantial literature in pigmentation and inflammatory signaling research.

Because KPV is very short, researchers have used it as a tool to ask whether specific activities observed with the full α-MSH peptide can be attributed to that terminal sequence.

α-MSH is a thirteen-amino-acid peptide produced from proopiomelanocortin (POMC). Beyond its classical role in pigmentation, work from the 1990s onward reported effects on inflammatory signaling in experimental systems.

That work prompted fragment studies. KPV emerged as the most-studied C-terminal fragment because it retained measurable activity in several of the assays used with the parent peptide while lacking its pigmentation-related properties.

The most frequently investigated proposed mechanism involves NF-κB, a transcription factor complex that regulates the expression of many inflammation-associated genes. Cell studies have measured NF-κB pathway activation markers in the presence of KPV.

Some studies have examined whether KPV acts through melanocortin receptors, as α-MSH does, while others report activity in systems where those receptors are not the obvious route — including work on peptide transporter–mediated cellular uptake, such as the PepT1 transporter in intestinal epithelial cells. The receptor question is not fully resolved.

Readouts commonly include cytokine levels in cell supernatants and inflammatory markers in rodent colitis models.

Inflammatory signaling research — NF-κB and cytokine expression in cell systems.

Gastrointestinal models — experimental colitis in rodents.

Epithelial cell biology and peptide transporter research.

Melanocortin system pharmacology as a comparative context.

Antimicrobial activity assays reported for some melanocortin-derived sequences in vitro.

Essentially all KPV-specific findings come from in-vitro cell work and rodent models. These describe experimental systems under controlled conditions.

There is no meaningful body of controlled human clinical trial evidence for KPV. No conclusions about effects in people are supported by the current literature.

Human research on the broader melanocortin system exists but concerns different molecules and does not transfer to KPV.

The receptor or transporter route responsible for observed effects has not been conclusively established.

Short peptides face substantial stability and delivery challenges in biological systems, which complicates interpretation of model results.

Study designs and endpoints vary considerably across the small literature.

Human data is absent.

KPV is the Lys-Pro-Val tripeptide corresponding to the C-terminal region of α-MSH, studied as a minimal fragment of that peptide.

Inflammatory signaling — particularly NF-κB pathway readouts — is the dominant research theme, in cell and rodent systems.

Mechanistic details remain open and human evidence is absent.

This page is provided for scientific and educational purposes only. It summarizes published laboratory research and does not constitute medical advice, does not describe any approved therapy, and does not provide instructions for human use of any kind.

SFVLAB supplies this compound strictly as a research-use-only material for laboratory investigation.